Fujifilm Diosynth Biotechnologies announced that its College Station, Texas, site will manufacture a COVID-19 vaccine candidate under a $265 million federal contract.
The contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies said it received the federal task order through the Texas A&M System Center for Innovation in Advanced Development & Manufacturing (CIADM), a public-private partnership between the government’s Biomedical Advanced Research and Development Authority (BARDA) and the university. CIADM subcontracts manufacturing to the Fujifilm Diosynth Biotechnologies’ owned-and-operated flexible biomanufacturing facility in College Station. The task order reserves manufacturing at the plant capacity in through the end of 2021.
Get the full story on our sister site, Pharmaceutical Processing World.